RecruitingEarly Phase 1NCT02356653

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells


Sponsor

Children's Hospital of Philadelphia

Enrollment

100 participants

Start Date

Dec 1, 2013

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.


Eligibility

Max Age: 30 Years

Plain Language Summary

Simplified for easier understanding

This trial is offering stem cell transplants using donor cells that have been specially filtered to remove certain immune cells (CD3+ and CD19+ cells), for patients who need a transplant but are not eligible for other available studies. **You may be eligible if...** - You do not have a fully matched sibling donor - You need a donor stem cell transplant but do not qualify for other current clinical studies using the same technique - You have one of these conditions: a metabolic storage disease, bone marrow failure syndrome, immune deficiency, hemoglobin disorder (like sickle cell), or blood cancer such as leukemia or lymphoma **You may NOT be eligible if...** - A fully matched sibling donor is available to you - You are eligible for another open institutional study using the same transplant approach - Your general health is too poor to undergo transplant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALTransplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.


Locations(1)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02356653


Related Trials